Bli medlem
Bli medlem

Du är här


MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on 8 May 2015 according to sec. 121 para. 4a AktG with the objective of Europe-wide di

MorphoSys AG / MorphoSys AG: Announcement of the Convening of the AGM in
Munich/Germany on 8May 2015 according to sec. 121 para. 4a AktG with the
objective of Europe-wide distribution. Processed and transmitted by NASDAQ
OMX Corporate Solutions. The issuer is solely responsible for the content of
this announcement.
MorphoSys AG Martinsried/Planegg Securities Code Number: 663200 ISIN:

Convenience Translation: The text decisive for the invitation to the Annual
General Meeting of MorphoSys AG is the one written in the German language.

Invitation to the Annual General Meeting 2015 of MorphoSys AG We hereby invite the shareholders of our Company to the Annual General Meeting
taking place on Friday, 8 May 2015 at 10:00 a.m., at the Conference Center
Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.


1 Presentation of the adopted financial statements and the approved
consolidated financial statements as of 31 December 2014; the management
reports, including the report of the Supervisory Board for the 2014
financial year; and the explanatory report of the Management Board
regarding the disclosures pursuant to sections 289 para. (4) and 315 para.
(4) German Commercial Code (HGB)
2 Resolution on the appropriation of the accumulated income of MorphoSys AG
for the 2014 financial year
3 Resolution on the discharge of the members of the Management Board with
respect to the 2014 financial year
4 Resolution on the discharge of the members of the Supervisory Board with
respect to the 2014 financial year
5 Resolution on the appointment of the auditor for the 2015 financial year
6 Resolution on the cancelation of Authorized Capital 2013-I and the creation
of new Authorized Capital 2015-I with the option to exclude the pre-emptive
rights of shareholders; amendments to the Articles of Association
7 Resolution on the election of Supervisory Board members
8 Resolution on the adjustment in remuneration of the Supervisory Board
9 Resolution on the amendments to the Articles of Association

Please find the full text of the invitation MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 90 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,arYla
®, Ylanthia®and 100 billion high potentials®are registered trademarks of
MorphoSys AG.

Slonomics®is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Mario Brkulj
Associate Director Corporate Communications&IR

Alexandra Goller
Manager Corporate Communications&IR

Jessica Rush
Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.